Lack of evidence of viability and infectivity of SARS-CoV-2 in the fecal specimens of COVID-19 patients

Madhuri Joshi1, Sreelekshmy Mohandas2, Sharda Prasad3, Manohar Shinde1, Nutan Chavan1, Pragya D. Yadav2† and Mallika Lavania1†

SARS-CoV-2 can be shed in feces and can enter sewage systems. In order to implement effective control measures and identify new channels of transmission, it is essential to identify the presence of infectious virus particles in feces and sewage. In this study, we attempt to utilize Molecular techniques and animal models to find out the infectivity of SARS-CoV-2 in the feces of COVID-19 patients. Our findings exclude the presence of infectious virus particles, suggesting that fecal-oral transmission may not be the main mode of transmission. Larger-scale initiatives are nevertheless required, particularly considering the emergence of new viral strains.

KEYWORDS
SARS-CoV-2, COVID-19, fecal, Real time RT–PCR, TEM, NGS

Assessments of the magnitude of ecological contamination by viruses are inside the domain of environmental virology. As we comprehend the genuine significance of viruses, proper control measures can be implemented to lessen the public health hazards. The first instance of Coronavirus disease 2019 (COVID-19) was discovered in China in December 2019, and it has since spread across the globe. COVID-19 cases totaled 563,107,209 worldwide as of July 13, 2022, including 43,672,155 in India (1). As the pandemic situation of COVID-19 worsened, it was suggested that along with the respiratory route alternative channels of transmission, such as fecal-oral and airborne transmission, may exist. For Coronavirus like SARS-CoV and MERS-CoV, the fecal-oral route was previously accepted as a method of transmission (2–4). The detection of SARS-CoV-2 RNA in anal/rectal swabs (5), stool samples (6–9) and wastewater/sewage (10, 11), along with studies demonstrating a high detection rate and viral levels equivalent to earlier SARS epidemics in fecal samples, of COVID-19 patients has been documented. Shared restrooms were blamed in one study for high rates of familial clustering (12, 13). Similarly, a longer duration of detection of SARS-CoV-2 RNA in feces as compared to respiratory specimens documented (14–16) may possibly suggest that the virus may be actively replicating in the patient’s gastrointestinal tract and that fecal–oral transmission might occur after viral clearance in the respiratory tract. In our previous study with a 62% fecal detection rate, no significant difference in mean duration of RNA detection...
in the GI tract asymptomatic and symptomatic cases of COVID-19 was documented (16). The studies on asymptomatic individuals as infectious during the early stage of infection were reported with rare cases becoming long-term virus carriers and lead to an apparent spread of the virus similar to symptomatic cases (17). The possibility of rare long-term carriers becoming virus reservoirs, with the potential to cause recurrent outbreaks, needs to be studied and will have important implications for future SARS-CoV-2 public health and surveillance, and our understanding of the SARS-CoV-2 virus. In developing countries due to a majority of asymptomatic infections and crowded places, the possibility of the fecal-oral route of transmission of SARS-CoV-2 may be high and prompted us to explore the possibility of viable infectious virions in fecal material.

In the present study [ethically approved by ICMR-NIV Ethics committee: 20-2-2 R], fecal specimens of COVID-19 patients were subjected to RT-PCR, digital RT-PCR, Next Generation sequencing (NGS), isolation in cells and animal models, and electron microscopic studies. Ten fecal specimens of COVID-19 patients (aged between 5 and 70 years) admitted in COVID-19 Care Center in Pune City, Maharashtra state, India during the second wave period [Jun-Aug 2021] were included in the study. Among ten patients, six were experiencing symptoms like fever, cough, sore throat, chest pain, wheezing, abdominal pain, vomiting/nausea, diarrhea, loss of taste and smell, while the remaining four were asymptomatic (Table 1). SARS-CoV-2 strains were detected using E and ORF gene based Real Time Reverse Transcription Polymerase chain reaction (RT-PCR) assays in paired throat and fecal specimens using protocols described earlier (18). The testing of throat swabs and fecal specimens (collected between 0 and 6 post onset day) was performed at the National Influenza Center, NIV, Pune. All throat swab specimens were positive with Ct values between 18–27 and 21–29 for E gene and ORF region respectively and fecal specimens with Ct values 19.5–25.9 and 22.6–28.1 for E gene and ORF region of SARS-CoV-2 respectively (Table 1).

The viral RNA load in the fecal specimens was estimated using N gene based digital RT-PCR assay as per manufacturer’s instructions (SARS-CoV-2 N1 + N2 Primer Probe Assay Kit, Qiagen, Germany). Thermal cycling was performed at 50°C for 40 min for reverse transcription, followed by 95°C for 2 min and then 40 cycles of 95°C for 5 s and 60°C for 30 s. Analysis of the viral RNA load in fecal specimens indicated 5526.2–15.2 copies/μL of RNA.

The Ion AmpliSeq technology and the Ion Torrent personal genome machine were used to sequence the genome of SARS-CoV-2 (PGM) (19). The data obtained was evaluated using the entire genome of the SARS-CoV-2 Wuhan-Hu-1 isolate after sequencing (GenBank accession number MN908947.3). Five specimens with >90% coverage yielded consensus of the whole genome data of SARS-CoV-2 and the remaining five were with partial genomes (mean genome length: 60.5%; Table 1). During dominance of the B.1.617.2 (Delta) and B.1.617.3 strains in the second wave of the COVID-19 pandemic in India (19), seven patients were infected with B.1.617.2 (Delta) strain, while the other two were infected with Kappa and one strain remained unassigned (Table 1). The entire sequence database has submitted in EpiFlu of GISAID [https://www.gisaid.org/epiflu-applications/submitting-data-to-epiflu.html] global database [EPI_ISL_13964608-13964611].

The successful isolation of multiple strains of SARS-CoV-2 has been performed using Vero CCL-81 cell lines at Indian Council of Medical Research- National Institute of Virology (ICMR-NIV), Pune City, Maharashtra state, India (20). We attempted isolation of SARS-CoV-2 from fecal specimens in Vero CCL-81 cell lines (21). Similarly, attempts were made to infect Syrian Hamsters using protocols reported earlier (22). However, in spite of multiple efforts, isolation attempts were not successful. It has been documented using cell culture and animal models that infectious viral particles were not recovered from feces at the peak of infection, despite the infectious virus being recovered from respiratory specimens (23–26). Isolation of viable SARS-CoV-2 from a stool sample of a COVID-19 patient has been documented about 15 days after onset of disease (27). The failure to isolate SARS-CoV-2 using cell culture or animal models may also be due to very low viral concentrations. It has been documented that specimens containing <10⁶ copies per ml never yielded an isolate (23). It should be noted that all the specimens were collected before the 6th post-onset day in the present study and viral load was <10⁴ copies per ml.

The failure to isolate the virus has also been attributed to factors such as sampling bias, presence of inhibitor, and/or cytotoxicity of fecal specimens, etc. In future, fecal specimens spiked with virulent SARS-CoV-2 viral particles for attempts to re-isolate using cell culture and animal models needs to be done to confirm the same.

The transmission electron microscopic (TEM) analysis of the fecal specimens was carried out as described earlier (28). Samples were prefixed with one percent glutaraldehyde and negative stained, and the grid was examined under 100 KV in a TEM (Tecnai 12 BioTwin™; FEI, The Netherlands). Images were captured using a side-mounted 2k × 2k CCD camera (Megaview III, Olympus, Japan). TEM imaging of clarified and negatively stained feces specimens (n = 10) showed the presence of distinct Coronavirus particles in two specimens (Figure 1). The size of the virus particle was 55 nm and the spike peplomer projections were ∼20 nm in length. The frequency of detection of morphologically identifiable coronavirus particles was, however, quite low. In most of the samples, phage particles and bacterial debris in the form of disintegrated flagella and capsular material were observed. Wang et al. documented isolation of SARS-CoV-2 from stool specimens of four patients and observed live virus in two specimens using electron microscopy (29). It should be noted that SARS-CoV-2 and other Coronavirus are indistinguishable morphologically from
| Sample ID  | Age/gender | POD | Admission signs and symptoms | Ct values of real time RT-PCR | NGS analysis | Lineage [variant] | EM analysis |
|------------|------------|-----|------------------------------|-------------------------------|--------------|------------------|-------------|
|            |            |     |                              | Throat swab                  |              |                  |             |
|            |            |     |                              | E gene | ORF gene       | E gene | ORF gene       |             |
| BR-21-195  | 65/M       | 3   | Fever, cough, lower chest wall indrawing, diarrhea, loss of taste, smell | 26      | 28             | 19.5   | 22.7            | 13857       |
| BR-21-200  | 5/F        | 0   | Fever, cough, bloody/ hemoptysis, sore throat, runny nose, abdominal pain, diarrhea, loss of taste, smell | 20      | 22             | 19.8   | 23.2            | 28237       |
| BR-21-238  | 7/M        | 3   | Asymptomatic                 | 23      | 25             | 21     | 24.7            | 20314       |
| BR-21-555  | 24/M       | 3   | Fever, cough, runny nose, altered consciousness/confusion, vomiting/nausea, diarrhea, new loss of taste and smell | 21      | 29             | 23.3   | 25.3            | 27370       |
| BR-21-537  | 8/M        | 6   | Fever, cough, sore throat, chest pain, wheezing, abdominal pain, vomiting/nausea, loss of taste and smell | 18      | 21             | 25.9   | 28.1            | 27825       |
| BR-21-772  | 70/M       | 6   | Asymptomatic                 | 25      | 26             | 25.9   | 28.1            | 27172       |
| BR-21-803  | 28/M       | 1   | Fever, cough                 | 27      | 28             | 23.3   | 25.3            | 14254       |
| BR-21-813  | 32/M       | 3   | Asymptomatic                 | 23      | 27             | 23.5   | 27.1            | 15536       |
| BR-21-815  | 14/M       | 1   | Asymptomatic                 | 25      | 28             | 21.6   | 24.4            | 26393       |
| BR-21-820  | 39/M       | 2   | Fever, cough                 | 25      | 27             | 20.1   | 22.6            | 17429       |
FIGURE 1. Transmission electron microscopy imaging from fecal specimen of positive COVID-19 patients.

Observation:
Distinct Corona virus
55nm core to spike
GP. Intact particle

The studies on presence of intact and infectious virion in fecal specimens are very scant. The electron microscopic technique used in the present study to visualize the intact coronavirus-like particles is a very time-consuming, labor-intensive process and requires a high level of skilled individuals. Similarly, for animal immunization and cell culture studies, handling of multiple specimens at a time is not possible and not recommended due to the possibility of cross contamination as the virus is replicating during passaging. Therefore, only
10 fecal specimens of COVID-19 patients were tested in the present study.

Even though several reports from different countries on the presence and persistence of SARS-CoV-2 in fecal/wastewater/sewage specimens are documented, a link is yet to be established between the spread of the infective virus from fecal specimens to the community. In this study, successful amplification of the full genome/nearly full genome and identification of the complete virion morphologically using TEM analysis in two specimens indicate the fecal excretion of the complete virion. However, the viability of the SARS-CoV-2 virion in fecal specimens was not confirmed using cell culture and animal studies. Future studies on a large number of fecal samples with high viral load as well as with late post-onset days needs to be done to explore the possibility of infection due to SARS-CoV-2 and to know its natural environmental persistence and infectivity in community settings.

Data availability statement

The original contributions presented in the study are publicly available. This data can be found here: https://www.gisaid.org/epiflu-applications/submitting-data-to-epiflutm/EPI_ISL_13964608-13964611.

Ethics statement

The studies involving human participants were reviewed and approved by ICMR-National Institute of Virology Ethical Committee. The patients/participants provided their oral/written informed consent to participate in this study.

Author contributions

ML contributed in the conception of the work, experimentation was done by MJ, MS, and NC. SM contributed in the isolation of SARS-CoV-2 from fecal specimens. SP did the TEM experimentation work and analysis. Manuscript writing done by MJ and ML. All authors contributed to the article and approved the submitted version.

References

1. COVID-19 Coronavirus Pandemic. Available online at: https://www.worldometers.info/coronavirus (assessed July 13, 2022).
2. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. (2003) 361:1767-72. doi: 10.1016/S0140-6736(03)13411-5
3. Chan PK, To WK, Ng KC, Lam RK, Ng TK, Chan RC, et al. Laboratory diagnosis of SARS. Emerg Infect Dis. (2004) 10:825-31. doi: 10.3201/eid1005.030682
4. Goh GK, Dunker AK, Uversky V. Prediction of intrinsic disorder in MERS-CoV/HCov-EMC supports a high oral-fecal transmission. PLoS Curr. (2013) 5:aaf498b. doi: 10.1371/currents.outbreaks.2254b58675cdeb7c36dbec35aa649bb

Funding

This study was funded by the ICMR-National Institute of Virology, Pune, Maharashtra, India and Indian Council of Medical Research, New Delhi, India.

Acknowledgments

We thank all patients involved in the study. Authors thank Prof. Dr. Priya Abraham, Director ICMR-NIV, Pune for all the support. We would like to thank Dr. Atanu Basu, Scientist G, Dr. Virendra Meena Scientist B (Electron Microscopy and Histopathology Group, ICMR-NIV) for EM imaging. Dr. Varsha Potadar, Scientist E, Influenza Group leader (ICMR-NIV), for conducting Real-time RT-PCR assays for Coronavirus other than SARS-CoV-2. The assistance provided by Mr. P. S. Jadhav and Ms. Shweta Bhosle during sample collection and data compilation from the hospital are duly acknowledged.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.1030249/full#supplementary-material
5. Jung SH, Kim SW, Lee H, Oh JH, Lim J. Serial screening for SARS-CoV-2 in rectal swabs of symptomatic COVID-19 patients. J Korean Med Sci. (2021) 36.e301. doi: 10.3346/jkms.2021.36.e301

6. Parasa S, Desai M, Thoguluva CV, Patel HK, Kennedy KE, Roesch T, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis. JAMA Netw. Open. (2020) 3:e2013135. doi: 10.1001/jamanetworkopen.2020.13335

7. Cevik M, Tase M, Lloyd O, Marasol AE, Schafer J, Ho A. SARS-CoV-2, SARS-CoV, and MERSCoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. (2021) 2:e13–22. doi: 10.1016/S2666-5247(20)30172-5

8. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. (2020) 26:502–5. doi: 10.1038/s41591-020-0817-4

9. Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. (2020) 92:833–40. doi: 10.1002/jmv.25825

10. Ahmed W, Angel N, Edson J, Bibby K, Bivins A, O’Brien JW, et al. First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: a proof of concept for the wastewater surveillance of COVID-19 in the community. Sci Total Environ. (2020) 728:138764. doi: 10.1016/j.scitotenv.2020.138764

11. Arora S, Nag A, Sethi J, Rayavanji J, Saxena S, Shrivastava SK, et al. Sewage surveillance for the presence of SARS-CoV-2 genome as a useful wastewater based epidemiology (WBE) tracking tool in India. Water Sci Technol. (2020) 82:2823–36. doi: 10.2166/wst.2020.540

12. Del Brutto OH, Costa AF, Garcia HH. Incident SARS-CoV-2 infection and a shared latrine. Am J Trop Med Hyg. (2020) 103:941–2. doi: 10.4269/ajtmh.20-0793

13. Amoah ID, Pillay L, Deepnarain N, Awolesi O, Pillay K, Ramlal P, et al. Detection of SARS-CoV-2 RNA on contact surfaces within shared sanitation facilities. Int J Hyg Environ Health. (2021) 236:113807. doi: 10.1016/j.ijheh.2021.113807

14. Wu Y, Guo C, Tang I, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-CoV-2 viral RNA in fecal samples. Lancet Gastroenterol Hepatol. (2020) 5:344–5. doi: 10.1016/S2468-1253(20)30083-2

15. Ranshing S, Lavanja M, Potdar V, Patwardhan S, Prayag PS, Jog S, et al. Transmission of COVID-19 infection within a family cluster in Pune, India. Indian J Med Res. (2021) 153:555–8. doi: 10.4103/ijmr.IJMR_3378_20

16. Lavanja M, Joshi MS, Ranshing SS, Potdar VA, Shinde M, Chavan N, et al. Prolonged shedding of SARS-CoV-2 in feces of COVID-19 positive patients: trends in genomic variation in first and second wave. Front Med. (2022) 9:835168. doi: 10.3389/fmed.2022.835168

17. Muller CP. Do asymptomatic carriers of SARS-CoV-2 transmit the virus? Lancet Reg Health Eur. (2021) 4:100082. doi: 10.1016/j.lanepe.2021.100082

18. Choudhary ML, Vipat V, Jadhav S, Basu A, Cherian S, Abraham P, Potdar VA. Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India. Indian J Med Res. (2020) 151:251–4. doi: 10.4103/ijmr.IJMR_671_20

19. Potdar V, Vipat V, Ramdasai A, Jadhav S, Pawar-Patil J, Walmbe A, et al. Phylogenetic classification of the whole-genome sequences of SARS-CoV-2 from India and evolutionary trends. Indian J Med Res. (2021) 153:666–74. doi: 10.4103/ijmr.IJMR_3418_20

20. Lavanja M, Potdar VA, Ranshing S, Vipat V, Saha U, Jadhav SM, et al. Whole-genome sequencing and mutational analysis of SARS-CoV-2 from patients’ fecal samples reveal the possible role in fecal-oral transmission. Indian J Med Res. (2021) 155:205–10. doi: 10.4103/ijmr.IJMR_1045_21

21. Sarkale P, Patil S, Yadav PD, Nyayanit DA, Sapkal G, Baradkar S, et al. First isolation of SARS-CoV-2 from clinical samples in India. Indian J Med Res. (2020) 151:244–50. doi: 10.4103/ijmr.IJMR_1029_20

22. Yadav PD, Gupta N, Potdar V, Mohandas S, Sahay RR, Sarkale P, et al. Isolation and genomic characterization of SARS-CoV-2 omicron variant obtained from human clinical specimens. Viruses. (2022) 14:461. doi: 10.3390/v14030461

23. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA. Virological assessment of hospitalized patients with COVID-19. Nature. (2020) 581:465–9. doi: 10.1038/s41586-020-2196-x

24. Richard M, Kok A, de Meulder D, Bestebroer TM, Lamers MM, Okba NMA, et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun. (2021) 11:3496. doi: 10.1038/s41467-020-17367-2

25. Sia SF, Yan LM, Chin AW, Fung K, Choy KT, Wong AYL, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. (2020) 583:834–8. doi: 10.1038/s41586-020-2342-5

26. Albert S, Ruiz A, Peinán J, Salvarti M, Domingo-Calap P. Lack of evidence for infectious SARS-CoV-2 in feces and sewage. Eur J Clin Microbiol Infect Dis. (2021) 40:2665–7. doi: 10.1007/s10018-021-04304-4

27. Zhang Y, Chen C, Zhu S, Shu C, Wang D, Song J, et al. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19). China CDC Weekly. (2020) 2:123–4. doi: 10.46234/ccdcw2020.033

28. Prasad S, Potdar V, Cherian S, Abraham P, Basu A, ICMR-NIV NIC Team. Transmission electron microscopy imaging of SARS-CoV-2. Indian J Med Res. (2021) 153:1–5. doi: 10.4103/ijmr.IJMR_577_20

29. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. (2020) 323:1061–9. doi: 10.1001/jama.2020.1585

30. van Elden LI, van Loon AM, van Alphen F, Hendriksen KA, Hooperman AI, van Kraaij MG. Frequent detection of human coronaviruses in clinical samples from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis. (2004) 189:652–7. doi: 10.1086/312025

31. Gunson RN, Collins TC, Carman WF. Real-time RT-PCR detection of 12 respiratory viral infections in four triplex reactions. J Clin Virol. (2005) 33:341–4. doi: 10.1016/j.jcv.2004.11.025